Premium
CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL
Author(s) -
Jacobsen E.,
Ďuraš J.,
Ardeshna K.,
Cherry M.,
Offner F.,
Mayer J.,
Bijou F.,
Tani M.,
Musuraca G.,
Merli M.,
Marasca R.,
Weaver D.T.,
Lustgarten S.,
Youssoufian H.,
Zinzani P.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.70_2631
Subject(s) - medicine , gastroenterology , clinical endpoint , refractory (planetary science) , phases of clinical research , population , adverse effect , regimen , progression free survival , oncology , clinical trial , surgery , chemotherapy , physics , environmental health , astrobiology
S312 IBCL-025 Standardized Uptake Value Calculated from In-Ibritumomab Tiuxetan SPECT/CT is a Very Useful Predictor for Therapeutic Efficacy and Post-Treatment Neutropenia in Patients Treated by Y-IT Ayaka Kume , Akira Toriihara, Ryo Shimizu, Naoki Harata, Jun Isogai, Hiroaki Tanaka Department of Hematology, Asahi General Hospital, Chiba, Japan; PET Imaging Center, Asahi General Hospital, Chiba, Japan; Department of Radiology, Asahi General Hospital, Chiba, Japan